DK3255043T3 - N-(6-((2r,3s)-3,4-dihydroxybutan-2-yloxy)-2-(4-fluorbenzylthio)pyrimidin-4-yl)-3-methylazetidin-1-sulfonamid som kemokinreceptormodulator - Google Patents

N-(6-((2r,3s)-3,4-dihydroxybutan-2-yloxy)-2-(4-fluorbenzylthio)pyrimidin-4-yl)-3-methylazetidin-1-sulfonamid som kemokinreceptormodulator Download PDF

Info

Publication number
DK3255043T3
DK3255043T3 DK16202983.9T DK16202983T DK3255043T3 DK 3255043 T3 DK3255043 T3 DK 3255043T3 DK 16202983 T DK16202983 T DK 16202983T DK 3255043 T3 DK3255043 T3 DK 3255043T3
Authority
DK
Denmark
Prior art keywords
dihydroxybutan
fluorobenzylthio
methylazetidin
sulphonamide
yloxy
Prior art date
Application number
DK16202983.9T
Other languages
English (en)
Inventor
Stephen Connolly
Mark Richard Ebden
Thomas Langer
Alan Robert Steven
Craig Robert Stewart
Paula Margaret Tomlin
Iain Alastair Stewart Walters
Andrew John Williams
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK3255043T3 publication Critical patent/DK3255043T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/21—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/20—Free hydroxyl or mercaptan
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/24—Radicals substituted by singly bound oxygen or sulfur atoms esterified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/26—Radicals substituted by doubly bound oxygen or sulfur atoms or by two such atoms singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/78—Benzoic acid esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/12—Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
DK16202983.9T 2011-07-12 2012-07-10 N-(6-((2r,3s)-3,4-dihydroxybutan-2-yloxy)-2-(4-fluorbenzylthio)pyrimidin-4-yl)-3-methylazetidin-1-sulfonamid som kemokinreceptormodulator DK3255043T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161506737P 2011-07-12 2011-07-12
EP12735323.3A EP2731945A1 (en) 2011-07-12 2012-07-10 N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio) pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator

Publications (1)

Publication Number Publication Date
DK3255043T3 true DK3255043T3 (da) 2021-03-29

Family

ID=46513787

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16202983.9T DK3255043T3 (da) 2011-07-12 2012-07-10 N-(6-((2r,3s)-3,4-dihydroxybutan-2-yloxy)-2-(4-fluorbenzylthio)pyrimidin-4-yl)-3-methylazetidin-1-sulfonamid som kemokinreceptormodulator

Country Status (37)

Country Link
US (3) US8735413B2 (da)
EP (2) EP3255043B1 (da)
JP (2) JP6006308B2 (da)
KR (1) KR101946664B1 (da)
CN (1) CN103781781B (da)
AR (2) AR087168A1 (da)
AU (2) AU2012282316B2 (da)
BR (1) BR112014000636B1 (da)
CA (1) CA2841859C (da)
CL (1) CL2014000079A1 (da)
CO (1) CO6852072A2 (da)
CR (1) CR20140007A (da)
CU (2) CU24292B1 (da)
CY (1) CY1124329T1 (da)
DK (1) DK3255043T3 (da)
DO (1) DOP2013000308A (da)
EA (1) EA027821B1 (da)
EC (1) ECSP14013130A (da)
ES (1) ES2861927T3 (da)
HK (1) HK1245779A1 (da)
HR (1) HRP20210413T1 (da)
HU (1) HUE053703T2 (da)
IL (1) IL230398A (da)
LT (1) LT3255043T (da)
MX (2) MX353334B (da)
MY (1) MY180039A (da)
NI (1) NI201400002A (da)
PE (2) PE20181069A1 (da)
PL (1) PL3255043T3 (da)
PT (1) PT3255043T (da)
RS (1) RS61608B1 (da)
SG (1) SG10201605619XA (da)
SI (1) SI3255043T1 (da)
TW (2) TWI659026B (da)
UY (1) UY34191A (da)
WO (1) WO2013008002A1 (da)
ZA (1) ZA201401059B (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG186859A1 (en) 2010-07-13 2013-02-28 Astrazeneca Ab New crystalline forms of n-[2-[[(2,3-difluoropheny)methyl)thio]-6-{[(1r,2s)-2,3-dihydroxy-1- methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide
MY180039A (en) * 2011-07-12 2020-11-20 Astrazeneca Ab N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio) pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator
EP2740458B1 (en) * 2012-12-06 2016-08-03 IP Gesellschaft für Management mbH Packaging comprising forms of sodium salt of 4-tert-butyl-N-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzenesulfonamide
MX2018010946A (es) * 2016-03-11 2019-05-23 Ardea Biosciences Inc Inhibidores de cxcr-2 para tratamiento de trastornos de artropatia por cristales.
CN111356675A (zh) * 2017-09-12 2020-06-30 阿迪亚生命科学公司 用于治疗病症的cxcr-2抑制剂
JP7336541B2 (ja) 2019-06-12 2023-08-31 ヌーリオン ケミカルズ インターナショナル ベスローテン フェノーツハップ 過酸化ジアシルを生成するためのプロセス
HUE063796T2 (hu) 2019-06-12 2024-01-28 Nouryon Chemicals Int Bv Eljárás diacil-peroxidok elõállítására
EP3983340B1 (en) * 2019-06-12 2023-08-02 Nouryon Chemicals International B.V. Method for isolating carboxylic acid from an aqueous side stream

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3457278A (en) * 1964-10-15 1969-07-22 Geigy Chem Corp Cyclopropyl-4-sulfanilamido-pyrimidines
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
NZ330868A (en) 1996-02-13 2000-01-28 Zeneca Ltd 4-phenoxy, phenylthio or phenylamino substituted quinazoline derivatives ane medicaments useful as VEGF inhibitors
EP0885198B1 (en) 1996-03-05 2001-12-19 AstraZeneca AB 4-anilinoquinazoline derivatives
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
FI981521A0 (fi) * 1998-07-01 1998-07-01 Orion Corp Substituoidut beta-diketonit ja niiden käyttö
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
US7030123B2 (en) 2000-05-31 2006-04-18 Astrazeneca Ab Indole derivatives with vascular damaging activity
AU6623301A (en) 2000-07-07 2002-01-21 Angiogene Pharm Ltd Colchinol derivatives as vascular damaging agents
PL359181A1 (en) 2000-07-07 2004-08-23 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
GB0217431D0 (en) 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
GB0419235D0 (en) * 2004-08-28 2004-09-29 Astrazeneca Ab Compounds
EP1809624B1 (en) * 2004-08-28 2013-11-20 AstraZeneca AB Pyrimidine sulphonamide derivatives as chemokine receptor modulators
ES2600804T3 (es) * 2006-01-19 2017-02-10 Orchid Pharma Limited Nuevos heterociclos
WO2008157273A1 (en) * 2007-06-14 2008-12-24 Smithkline Beecham Corporation Chemical compounds
CA2730477A1 (en) * 2008-07-16 2010-01-21 Astrazeneca Ab Pyrimidyl sulfonaminde derivative and its use for the treatment of chemokine mediated diseases
US20110124919A1 (en) 2008-07-25 2011-05-26 Basf Se 3-aminomethyl-1-cyclohexylamine, and method for the production thereof
SG186859A1 (en) * 2010-07-13 2013-02-28 Astrazeneca Ab New crystalline forms of n-[2-[[(2,3-difluoropheny)methyl)thio]-6-{[(1r,2s)-2,3-dihydroxy-1- methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide
MY180039A (en) * 2011-07-12 2020-11-20 Astrazeneca Ab N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio) pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator

Also Published As

Publication number Publication date
TWI659026B (zh) 2019-05-11
US20130040926A1 (en) 2013-02-14
PE20181069A1 (es) 2018-07-04
NZ619001A (en) 2016-05-27
KR101946664B1 (ko) 2019-02-11
SI3255043T1 (sl) 2021-04-30
CL2014000079A1 (es) 2014-06-27
AR124688A2 (es) 2023-04-26
CA2841859A1 (en) 2013-01-17
TW201825479A (zh) 2018-07-16
EA201490077A1 (ru) 2014-10-30
MY180039A (en) 2020-11-20
ES2861927T3 (es) 2021-10-06
TW201311670A (zh) 2013-03-16
PT3255043T (pt) 2021-03-29
NI201400002A (es) 2016-02-16
US9221782B2 (en) 2015-12-29
HK1245779A1 (zh) 2018-08-31
CN103781781B (zh) 2015-08-26
PE20141944A1 (es) 2014-12-24
CU20140004A7 (es) 2014-05-27
ZA201401059B (en) 2017-09-27
KR20140037915A (ko) 2014-03-27
TWI633098B (zh) 2018-08-21
EA027821B1 (ru) 2017-09-29
SG10201605619XA (en) 2016-08-30
CU20160083A7 (es) 2017-03-03
CN103781781A (zh) 2014-05-07
BR112014000636B1 (pt) 2022-08-30
US20140228339A1 (en) 2014-08-14
PL3255043T3 (pl) 2021-07-12
JP6261666B2 (ja) 2018-01-17
AR087168A1 (es) 2014-02-26
EP3255043B1 (en) 2021-01-20
MX2013015085A (es) 2014-01-24
HRP20210413T1 (hr) 2021-05-14
MX353334B (es) 2018-01-09
AU2016244246A1 (en) 2016-10-27
EP2731945A1 (en) 2014-05-21
BR112014000636A2 (pt) 2017-01-10
ECSP14013130A (es) 2014-02-28
US20160108023A1 (en) 2016-04-21
DOP2013000308A (es) 2014-02-28
UY34191A (es) 2013-02-28
AU2012282316B2 (en) 2016-07-14
AU2012282316A1 (en) 2013-05-02
JP2016190864A (ja) 2016-11-10
RS61608B1 (sr) 2021-04-29
MX342874B (es) 2016-10-17
CO6852072A2 (es) 2014-01-30
LT3255043T (lt) 2021-04-12
CU24292B1 (es) 2017-12-08
EP3255043A2 (en) 2017-12-13
AU2016244246B2 (en) 2017-11-23
WO2013008002A1 (en) 2013-01-17
JP2014520838A (ja) 2014-08-25
IL230398A (en) 2017-10-31
HUE053703T2 (hu) 2021-07-28
CR20140007A (es) 2014-05-14
EP3255043A3 (en) 2018-04-18
JP6006308B2 (ja) 2016-10-12
CY1124329T1 (el) 2022-07-22
NZ719176A (en) 2017-11-24
CA2841859C (en) 2021-03-09
US8735413B2 (en) 2014-05-27
US9975881B2 (en) 2018-05-22

Similar Documents

Publication Publication Date Title
DK3255043T3 (da) N-(6-((2r,3s)-3,4-dihydroxybutan-2-yloxy)-2-(4-fluorbenzylthio)pyrimidin-4-yl)-3-methylazetidin-1-sulfonamid som kemokinreceptormodulator
IL242278A0 (en) Compounds 4)-n-fluoro-2-methoxy-5-nitrophenyl)pyrimidine-2-converted amine and their salts
BRPI1013760A2 (pt) compostos anticâncer de amino pirimidina.
AP2012006192A0 (en) PyrroloÄ2,3-DÜ pyrimidine compounds.
DK2491037T3 (da) Quinazolin-4(3h)-onderivater, der anvendes som pi3-kinase-inhibitorer
BR112013025792A2 (pt) Inibidores de quinase relacionada à pirrolo[2,3-d] pirimidina tropomisina
BR112013015000A2 (pt) formas cristalinas de 5-cloron2-(2-isopropóxi-5-metil-4-piperidin-4-il-fenil)-n4-[2-(propano-2-sulfonil)-fenil]-pirimidina-2,4-diamina
BRPI0907364A2 (pt) Antagonistas aminoalquilbifenil n,n-disubstituídos de receptores d2 de prostaglandina
BRPI1010579A2 (pt) espiro-oxetano nucleosídeos de uracila.
CO6910204A2 (es) Derivados de 5-flúor-4-imino-3-(sustituido)-3,4-dihidropirimidin-2(1h)ona
ITMI20120074A1 (it) Apparecchio per la rappezzatura di piallaccio di compensato.
DK2579619T3 (da) Audiobearbejdende kompressionssystem, som anvender niveauafhængige kanaler
DK2735063T3 (da) Compton-lyskilder med høj strøm og smal båndvidde gennem udvidede laser-elektronstråleinteraktioner
FR2985007B1 (fr) Regenerateur.
BR112013019990A2 (pt) recipientes à base de poliolefinas.
EP2744334A4 (en) N- (5-fluoro-2 - ((4-methylbenzyl) oxy) pyrimidin-4-yl) benzamide derivatives
IT1401800B1 (it) Astuccio telescopico, particolarmente per occhiali.
IT1402020B1 (it) Portalampade, particolarmente per moduli led.
ITMI20110360A1 (it) Disposizione per connettere due componenti.
ITBO20110103U1 (it) Dispositivo di presa, particolarmente per attrezzi ginnici.
DK2785675T5 (da) 5,5-dimethyl-2-propyl-hexahydro-2,4a-methanonaphthalen-1-on som duftmiddel
GB201114946D0 (en) Tile, (psa) self adhesive
GB201109110D0 (en) Multi search, social share & multi check out
ES1075754Y (es) Ambientador por capilaridad, con colgador automontable
ES1076014Y (es) Mochila de espalda.